Breaking News, Collaborations & Alliances

Forest, Nabriva In Development Pact

Forest to fund development of antibacterial agent

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Forest Laboratories, Inc. and Nabriva Therapeutics have entered into an agreement for the development of Nabriva’s antibacterial agent, BC-3781. Forest will provide $25 million and fund and conduct in collaboration with Nabriva, certain development activities related to BC-3781 for the next 12 months, during which Forest has the exclusive right to acquire Nabriva. The transaction is subject to customary regulatory clearances.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters